Seres Therapeutics, Inc.MCRBNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank8
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P8
Near historical low
vs 5Y Ago
-1.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-26.37%
2024-31.38%
202310.30%
20221.45%
2021125.06%
202024.35%
2019-24.08%
2018-4.24%
20174.37%
201694.59%